BEGIN:VCALENDAR
PRODID:-//AddEvent Inc//AddEvent.com v1.7//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/Phoenix
BEGIN:STANDARD
DTSTART:19691231T170000
TZOFFSETFROM:-0700
TZOFFSETTO:-0700
TZNAME:MST
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Join National Jewish Health in person or via livestream for this CME symposium at CHEST 2026. Register at NJHealth.org/SevereAsthma  http://NJHealth.org/SevereAsthma\n\nSevere asthma is associated with substantial morbidity\, recurrent exacerbations\, and significant treatment burden despite available therapies. For many patients with Type 2 inflammation\, including eosinophilic phenotypes\, targeted biologic therapies have transformed the treatment landscape. Continued advances\, including biologic options with extended dosing intervals\, are introducing new considerations for individualized treatment selection\, treatment burden\, adherence\, and long-term disease control.\n\nIn this CME lunch symposium and live online broadcast\, an expert panel of pulmonologists and allergists will use case-based discussion to examine practical challenges in severe asthma management. Panelists will explore treatment selection and reassessment\, shared decision-making\, long-term disease control\, multidisciplinary collaboration\, and the impact of comorbidities and access barriers on patient outcomes.\n\n1.0 CME/MOC\n\nFaculty:\nPraveen Akuthota\, MD\nUC San Diego\n\nFlavia Hoyte\, MD\nUniversity of Florida\n\nEileen Wang\, MD\, MPH\nNational Jewish Health\n\nMichael E. Wechsler\, MD\, MMSc\nNational Jewish Health
X-ALT-DESC;FMTTYPE=text/html:<strong>Join National Jewish Health in person or via livestream for this CME symposium at CHEST 2026. Register at </strong><a href="http://NJHealth.org/SevereAsthma" target="_blank" rel="noopener noreferrer"><strong>NJHealth.org/SevereAsthma </strong></a><br><br>Severe asthma is associated with substantial morbidity, recurrent exacerbations, and significant treatment burden despite available therapies. For many patients with Type 2 inflammation, including eosinophilic phenotypes, targeted biologic therapies have transformed the treatment landscape. Continued advances, including biologic options with extended dosing intervals, are introducing new considerations for individualized treatment selection, treatment burden, adherence, and long-term disease control.<br><br>In this CME lunch symposium and live online broadcast, an expert panel of pulmonologists and allergists will use case-based discussion to examine practical challenges in severe asthma management. Panelists will explore treatment selection and reassessment, shared decision-making, long-term disease control, multidisciplinary collaboration, and the impact of comorbidities and access barriers on patient outcomes.<br><br>1.0 CME/MOC<br><br>Faculty:<br />Praveen Akuthota, MD<br />UC San Diego<br><br>Flavia Hoyte, MD<br />University of Florida<br><br>Eileen Wang, MD, MPH<br />National Jewish Health<br><br>Michael E. Wechsler, MD, MMSc<br />National Jewish Health
UID:fa5e62dd18de47c2b87158fc0785feb6addeventcom
SUMMARY:Rethinking Treatment Frequency in Severe Asthma: A Case-Based Discussion of Emerging Evidence and Clinical Implications
DTSTART;TZID=America/Phoenix:20261018T121500
DTEND;TZID=America/Phoenix:20261018T131500
DTSTAMP:20260926T224929Z
TRANSP:OPAQUE
STATUS:CONFIRMED
SEQUENCE:0
LOCATION:Phoenix Convention Center\nNorth Building Room #132\n100 N 3rd St\, Phoenix\, 85004\, AZ\, USA
X-MICROSOFT-CDO-BUSYSTATUS:BUSY
BEGIN:VALARM
TRIGGER:-PT60M
ACTION:DISPLAY
DESCRIPTION:Reminder
END:VALARM
END:VEVENT
END:VCALENDAR